Navigation Links
Kensey Nash to Participate in the Sidoti Thirteenth Annual New York Emerging Growth Institutional Investor Forum Conference
Date:3/13/2009

EXTON, Pa., March 13 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) is scheduled to present at the Sidoti Thirteenth Annual New York Emerging Growth Institutional Investor Forum at The Grand Hyatt in New York City on Tuesday, March 24, 2009.

Joseph W. Kaufmann, Kensey Nash's CEO, will deliver the Company's presentation, beginning at approximately 11:35 a.m. (ET). The presentation materials will be available on the company's website (www.kenseynash.com) beginning at 11:35 a.m. (ET) on Tuesday, March 24, 2009.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Kensey Nash Announces Appointment of Chief Financial Officer
2. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
3. Kensey Nash Announces Director Resignation
4. Kensey Nash Corporation Announces Its Second Quarter 2009 Earnings Release Date and Teleconference
5. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
6. Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2008 Earnings Release Date and Teleconference
7. Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance
8. Kensey Nash Announces the Closing on its Sale of the Endovascular Business to Spectranetics
9. Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference
10. Corrected Press Release: Kensey Nash to Present at the Bank of America 2008 Health Care Conference
11. Kensey Nash to Present at the Bank of America 2008 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... ... , ... Scientists from the University of Exeter reported this month ... equivalent to a medium-paced run for pre-menopausal women, or a slow jog for post-menopausal ... spine care, I understand the importance exercise can play on improving bone health. Although ...
(Date:7/23/2017)... Fla. (PRWEB) , ... July 23, 2017 , ... ... M.D., has joined Florida Pain Relief Group – Melbourne, a practice owned by ... board certification in interventional pain management, Dr. Stern also is certified in pediatrics, ...
(Date:7/22/2017)... ... July 22, 2017 , ... The arthroscopic superior capsule ... opportunity to return to sports and jobs that require heavy physical work, as ... Annual Meeting in Toronto, Ontario, Canada. , “We studied 100 patients ...
(Date:7/21/2017)... Orange Park, FL (PRWEB) , ... July 21, ... ... that provides insurance management assistance and financial planning services to families and business ... in a charity event that promises to provide support to area adults with ...
(Date:7/21/2017)... ... , ... Hospital M&A activity slowed in the second quarter of 2017, according ... to 23 in the second quarter, up 15% from the 20 publicly announced acquisitions ... in the year-ago second quarter. Only four of the transactions disclosed a purchase price ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of ... their families to thrive on nutrition support. To celebrate its ... new site has a fresh new look with improved organization to create ... ... ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral drug ... the Israel Securities Authority to dual-list its common stock on ... commence trading on the TASE on July 12, 2017 under ... the Company, it is expected that Oramed will be included ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
Breaking Medicine Technology: